Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Jazz Pharmaceuticals plc

J7Z
Current price
98.18 EUR +1.02 EUR (+1.05%)
Last closed 97.48 EUR
ISIN IE00B4Q5ZN47
Sector Healthcare
Industry Biotechnology
Exchange Frankfurt Exchange
Capitalization 6 072 733 601 EUR
Yield for 12 month -20.53 %
1Y
3Y
5Y
10Y
15Y
J7Z
21.11.2021 - 28.11.2021

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. Address: Waterloo Exchange, Dublin, Ireland, D04 E5W7

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

187.42 EUR

P/E ratio

18.1866

Dividend Yield

Current Year

+3 446 592 815 EUR

Last Year

+3 289 436 904 EUR

Current Quarter

+920 323 459 EUR

Last Quarter

+810 798 833 EUR

Current Year

+3 055 049 601 EUR

Last Year

+2 803 562 389 EUR

Current Quarter

+821 531 782 EUR

Last Quarter

+724 964 900 EUR

Key Figures J7Z

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 423 831 438 EUR
Operating Margin TTM 19.48 %
PE Ratio 18.1866
Return On Assets TTM 4.29 %
PEG Ratio 0.8072
Return On Equity TTM 10.84 %
Wall Street Target Price 187.42 EUR
Revenue TTM 3 910 035 122 EUR
Book Value 60.94 EUR
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 6.9 %
Dividend Yield
Gross Profit TTM 3 392 381 086 EUR
Earnings per share 5.36 EUR
Diluted Eps TTM 5.36 EUR
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY 64.3 %
Profit Margin 10.1 %

Dividend Analytics J7Z

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History J7Z

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation J7Z

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 18.1866
Forward PE 5.7307
Enterprise Value Revenue 2.6929
Price Sales TTM 1.5511
Enterprise Value EBITDA 8.6622
Price Book MRQ 1.7723

Financials J7Z

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators J7Z

For 52 weeks

92.4 EUR 131.26 EUR
50 Day MA 99.8 EUR
Shares Short Prior Month
200 Day MA 105.48 EUR
Short Ratio
Shares Short
Short Percent